We read with interest the Article by Giacomo Montagna and colleagues1 evaluating oncological outcomes in patients with residual nodal micrometastatic disease (ypN1mi) following neoadjuvant systemic therapy. Although the study contributes important data on axillary management, the recommendation favouring completion axillary lymph node dissection (ALND) in patients with triple-negative breast cancer warrants cautious interpretation given key limitations and conflicting evidence.
The Lancet Oncology published a clinical update in Oncology on 01 Apr 2026.
The item focuses on ALND after neoadjuvant chemotherapy: a call for caution.
Review the original article for the full source wording and details.